Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2014

Open Access 01-12-2014 | Research article

Comparison of cytotoxicity and genotoxicity of 4-hydroxytamoxifen in combination with Tualang honey in MCF-7 and MCF-10A cells

Authors: Nik Soriani Yaacob, Nur Faezah Ismail

Published in: BMC Complementary Medicine and Therapies | Issue 1/2014

Login to get access

Abstract

Background

The Malaysian Tualang honey (TH) is not only cytotoxic to human breast cancer cell lines but it has recently been reported to promote the anticancer activity induced by tamoxifen in MCF-7 and MDA-MB-231 cells suggesting its potential as an adjuvant for the chemotherapeutic agent. However, tamoxifen produces adverse effects that could be due to its ability to induce cellular DNA damage. Therefore, the study is undertaken to determine the possible modulation of the activity of 4-hydroxytamoxifen (OHT), an active metabolite of tamoxifen, by TH in non-cancerous epithelial cell line, MCF-10A, in comparison with MCF-7 cells.

Methods

MCF-7 and MCF-10A cells were treated with TH, OHT or the combination of both and cytotoxicity and antiproliferative activity were determined using LDH and MTT assays, respectively. The effect on cellular DNA integrity was analysed by comet assay and the expression of DNA repair enzymes was determined by Western blotting.

Results

OHT exposure was cytotoxic to both cell lines whereas TH was cytotoxic to MCF-7 cells only. TH also significantly decreased the cytotoxic effect of OHT in MCF-10A but not in MCF-7 cells. TH induced proliferation of MCF10A cells but OHT caused growth inhibition that was abrogated by the concomitant treatment with TH. While TH enhanced the OHT-induced DNA damage in the cancer cells, it dampened the genotoxic effect of OHT in the non-cancerous cells. This was supported by the increased expression of DNA repair proteins, Ku70 and Ku80, in MCF-10A cells by TH.

Conclusion

The findings indicate that TH could afford protection of non-cancerous cells from the toxic effects of tamoxifen by increasing the efficiency of DNA repair mechanism in these cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jiang Q, Zhong Q, Zhang Q, Zheng S, Wang G: Boron-based 4-Hydroxytamoxifen bioisosteres for treatment of de Novo Tamoxifen resistant breast cancer. ACS Med Chem Lett. 2012, 3: 392-396. 10.1021/ml3000287.CrossRefPubMedPubMedCentral Jiang Q, Zhong Q, Zhang Q, Zheng S, Wang G: Boron-based 4-Hydroxytamoxifen bioisosteres for treatment of de Novo Tamoxifen resistant breast cancer. ACS Med Chem Lett. 2012, 3: 392-396. 10.1021/ml3000287.CrossRefPubMedPubMedCentral
2.
go back to reference Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999, 17: 1474-1484.PubMed Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999, 17: 1474-1484.PubMed
3.
go back to reference Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009, 9: 631-643. 10.1038/nrc2713.CrossRefPubMed Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009, 9: 631-643. 10.1038/nrc2713.CrossRefPubMed
4.
go back to reference Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998, 351: 1451-1467.CrossRef Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998, 351: 1451-1467.CrossRef
5.
go back to reference White I: Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr Drug Metab. 2003, 4: 223-239. 10.2174/1389200033489451.CrossRefPubMed White I: Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr Drug Metab. 2003, 4: 223-239. 10.2174/1389200033489451.CrossRefPubMed
6.
go back to reference Omoti AE, Omoti CE: Ocular toxicity of systemic anticancer chemotherapy. Pharm Pract. 2006, 4: 55-59. Omoti AE, Omoti CE: Ocular toxicity of systemic anticancer chemotherapy. Pharm Pract. 2006, 4: 55-59.
7.
go back to reference Mizutani A, Okada T, Shibutani S, Sonoda E, Helfrid H, Nishigori C, Miyachi YB, Takeda SA, Yamazoe MA: Extensive chromosomal breaks are induced by tamoxifen and estrogen in DNA repair-deficient cells. Cancer Res. 2004, 64: 3144-3147. 10.1158/0008-5472.CAN-03-3489.CrossRefPubMed Mizutani A, Okada T, Shibutani S, Sonoda E, Helfrid H, Nishigori C, Miyachi YB, Takeda SA, Yamazoe MA: Extensive chromosomal breaks are induced by tamoxifen and estrogen in DNA repair-deficient cells. Cancer Res. 2004, 64: 3144-3147. 10.1158/0008-5472.CAN-03-3489.CrossRefPubMed
8.
go back to reference Carthew P, Lee PN, Edwards RE, Heydon RT, Nolan BM, Martin EA: Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. Arch Toxicol. 2001, 75: 375-380. 10.1007/s002040100244.CrossRefPubMed Carthew P, Lee PN, Edwards RE, Heydon RT, Nolan BM, Martin EA: Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat. Arch Toxicol. 2001, 75: 375-380. 10.1007/s002040100244.CrossRefPubMed
9.
go back to reference Wozniak K, Kolacinska A, Blasinska-Morawiec M, Morawiec-Bajda A, Morawiec Z, Zadrozny M, Blasiak J: The DNA-damaging potential of tamoxifen in breast cancer and normal cells. Arch Toxicol. 2007, 81: 519-527. 10.1007/s00204-007-0188-3.CrossRefPubMed Wozniak K, Kolacinska A, Blasinska-Morawiec M, Morawiec-Bajda A, Morawiec Z, Zadrozny M, Blasiak J: The DNA-damaging potential of tamoxifen in breast cancer and normal cells. Arch Toxicol. 2007, 81: 519-527. 10.1007/s00204-007-0188-3.CrossRefPubMed
10.
go back to reference Hoskins JM, Carey LA, McLeod HL: CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009, 9: 576-586. 10.1038/nrc2683.CrossRefPubMed Hoskins JM, Carey LA, McLeod HL: CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009, 9: 576-586. 10.1038/nrc2683.CrossRefPubMed
11.
go back to reference Gheldof N, Engeseth NJ: Antioxidant capacity of honeys from various floral sources based on the determination of oxygen radical absorbance capacity and inhibition of in vivo lipoprotein oxidation in human serum samples. J Agric Food Chem. 2002, 50: 3050-3055. 10.1021/jf0114637.CrossRefPubMed Gheldof N, Engeseth NJ: Antioxidant capacity of honeys from various floral sources based on the determination of oxygen radical absorbance capacity and inhibition of in vivo lipoprotein oxidation in human serum samples. J Agric Food Chem. 2002, 50: 3050-3055. 10.1021/jf0114637.CrossRefPubMed
12.
go back to reference Manyi-Loh CE, Clarke AM, Ndip RN: An overview of honey: Therapeutic properties and contribution in nutrition and human health. Afr J Microbiol Res. 2011, 5: 844-852. Manyi-Loh CE, Clarke AM, Ndip RN: An overview of honey: Therapeutic properties and contribution in nutrition and human health. Afr J Microbiol Res. 2011, 5: 844-852.
13.
go back to reference Swellam T, Miyanaga N, Onozawa M, Hattori K, Kwai K, Shimazui T, Akaza H: Antineoplastic activity of honey in an experimental bladder cancer implantation model: in vivo and in vitro studies. Int J Urol. 2003, 10: 213-219. 10.1046/j.0919-8172.2003.00602.x.CrossRefPubMed Swellam T, Miyanaga N, Onozawa M, Hattori K, Kwai K, Shimazui T, Akaza H: Antineoplastic activity of honey in an experimental bladder cancer implantation model: in vivo and in vitro studies. Int J Urol. 2003, 10: 213-219. 10.1046/j.0919-8172.2003.00602.x.CrossRefPubMed
14.
go back to reference Fukuda M, Kobayashi K, Hirono Y, Miyagawa M, Ishida T, Ejiogu EC, Sawai M, Pinkerton KE, Takeuchi M: Jungle honey enhances immune function and antitumor activity. Evid Based Complement Altern Med. 2011, 2011: 8-CrossRef Fukuda M, Kobayashi K, Hirono Y, Miyagawa M, Ishida T, Ejiogu EC, Sawai M, Pinkerton KE, Takeuchi M: Jungle honey enhances immune function and antitumor activity. Evid Based Complement Altern Med. 2011, 2011: 8-CrossRef
15.
go back to reference Fernandez-Cabezudo MJ, El-Kharrag R, Torab F, Bashir G, George JA, El-Taji H, Al-Ramadi BK: Intravenous administration of manuka honey inhibits tumor growth and improves host survival when used in combination with chemotherapy in a melanoma mouse model. PLoS One. 2013, 8: e55993-10.1371/journal.pone.0055993.CrossRefPubMedPubMedCentral Fernandez-Cabezudo MJ, El-Kharrag R, Torab F, Bashir G, George JA, El-Taji H, Al-Ramadi BK: Intravenous administration of manuka honey inhibits tumor growth and improves host survival when used in combination with chemotherapy in a melanoma mouse model. PLoS One. 2013, 8: e55993-10.1371/journal.pone.0055993.CrossRefPubMedPubMedCentral
16.
go back to reference Fauzi AN, Norazmi MN, Yaacob NS: Tualang honey induces apoptosis and disrupts the mitochondrial membrane potential of human breast and cervical cancer cell lines. Food Chem Toxicol. 2011, 49: 871-878. 10.1016/j.fct.2010.12.010.CrossRefPubMed Fauzi AN, Norazmi MN, Yaacob NS: Tualang honey induces apoptosis and disrupts the mitochondrial membrane potential of human breast and cervical cancer cell lines. Food Chem Toxicol. 2011, 49: 871-878. 10.1016/j.fct.2010.12.010.CrossRefPubMed
17.
go back to reference Yaacob NS, Fauzi AN, Norazmi MN: Tualang honey promotes apoptotic cell death induced by tamoxifen in human breast cancer cell lines. Evid Based Complement Altern Med. 2013, 2013: 989841-CrossRef Yaacob NS, Fauzi AN, Norazmi MN: Tualang honey promotes apoptotic cell death induced by tamoxifen in human breast cancer cell lines. Evid Based Complement Altern Med. 2013, 2013: 989841-CrossRef
18.
go back to reference Ghashm AA, Othman NH, Khattak MN, Ismail NM, Saini R: Antiproliferative effect of Tualang honey on oral squamous cell carcinoma and osteosarcoma cell lines. BMC Complement Altern Med. 2010, 10: 1-8. 10.1186/1472-6882-10-1.CrossRef Ghashm AA, Othman NH, Khattak MN, Ismail NM, Saini R: Antiproliferative effect of Tualang honey on oral squamous cell carcinoma and osteosarcoma cell lines. BMC Complement Altern Med. 2010, 10: 1-8. 10.1186/1472-6882-10-1.CrossRef
19.
go back to reference Kadir EA, Sulaiman SA, Yahya NK, Othman NH: Inhibitory effects of Tualang Honey on experimental breast cancer in rats: a preliminary study. Asian Pac J Cancer Prev. 2013, 14: 2249-2254. 10.7314/APJCP.2013.14.4.2249.CrossRefPubMed Kadir EA, Sulaiman SA, Yahya NK, Othman NH: Inhibitory effects of Tualang Honey on experimental breast cancer in rats: a preliminary study. Asian Pac J Cancer Prev. 2013, 14: 2249-2254. 10.7314/APJCP.2013.14.4.2249.CrossRefPubMed
20.
go back to reference Mohamed M, Sirajudeen KNS, Swamy M, Yaacob NS, Sulaiman SA: Studies on the antioxidant properties of Tualang honey of Malaysia. Afr J Tradit Complement Altern Med. 2010, 7: 59-63. 10.1625/jcam.7.59. Mohamed M, Sirajudeen KNS, Swamy M, Yaacob NS, Sulaiman SA: Studies on the antioxidant properties of Tualang honey of Malaysia. Afr J Tradit Complement Altern Med. 2010, 7: 59-63. 10.1625/jcam.7.59.
21.
go back to reference Bush NJ: Advances in hormonal therapy for breast cancer. Semin Oncol Nurs. 2007, 23: 46-54. 10.1016/j.soncn.2006.11.008.CrossRefPubMed Bush NJ: Advances in hormonal therapy for breast cancer. Semin Oncol Nurs. 2007, 23: 46-54. 10.1016/j.soncn.2006.11.008.CrossRefPubMed
22.
go back to reference Brown K: Is tamoxifen a genotoxic carcinogen in women?. Mutagenesis. 2009, 24: 391-404. 10.1093/mutage/gep022.CrossRefPubMed Brown K: Is tamoxifen a genotoxic carcinogen in women?. Mutagenesis. 2009, 24: 391-404. 10.1093/mutage/gep022.CrossRefPubMed
23.
go back to reference McLuckie KIE, Routledge MN, Brown K, Gaskell M, Farmer PB, Roberts GCK, Martin EA: DNA adducts formed from 4-hydroxytamoxifen are more mutagenic than those formed by α-acetoxytamoxifen in a shuttle vector target gene replicated in human Ad293 cells. Biochemistry. 2002, 41: 8899-8906. 10.1021/bi025575i.CrossRefPubMed McLuckie KIE, Routledge MN, Brown K, Gaskell M, Farmer PB, Roberts GCK, Martin EA: DNA adducts formed from 4-hydroxytamoxifen are more mutagenic than those formed by α-acetoxytamoxifen in a shuttle vector target gene replicated in human Ad293 cells. Biochemistry. 2002, 41: 8899-8906. 10.1021/bi025575i.CrossRefPubMed
24.
go back to reference Kim SY, Suzuki N, Laxmi YR, Shibutani S: Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev. 2004, 36: 199-218. 10.1081/DMR-120033997.CrossRefPubMed Kim SY, Suzuki N, Laxmi YR, Shibutani S: Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev. 2004, 36: 199-218. 10.1081/DMR-120033997.CrossRefPubMed
25.
go back to reference Bollig A, Xu L, Thakur A, Wu J, Kuo TH, Liao JD: Regulation of intracellular calcium release and PP1alpha in a mechanism for 4-hydroxytamoxifen-induced cytotoxicity. Mol Cell Biochem. 2007, 305: 45-54. 10.1007/s11010-007-9526-2.CrossRefPubMed Bollig A, Xu L, Thakur A, Wu J, Kuo TH, Liao JD: Regulation of intracellular calcium release and PP1alpha in a mechanism for 4-hydroxytamoxifen-induced cytotoxicity. Mol Cell Biochem. 2007, 305: 45-54. 10.1007/s11010-007-9526-2.CrossRefPubMed
26.
go back to reference Duan L, Motchoulski N, Danzer B, Davidovich I, Shariat-Madar Z, Levenson VV: Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells. J Biol Chem. 2011, 286: 2864-2876. 10.1074/jbc.M110.143271.CrossRefPubMed Duan L, Motchoulski N, Danzer B, Davidovich I, Shariat-Madar Z, Levenson VV: Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells. J Biol Chem. 2011, 286: 2864-2876. 10.1074/jbc.M110.143271.CrossRefPubMed
27.
go back to reference Petinari L, Kohn LK, Carvalho JE, Genari SC: Cytotoxicity of tamoxifen in normal and tumoral cell lines and its ability to induce cellular transformation in vitro. Cell Biol Int. 2004, 28: 531-539. 10.1016/j.cellbi.2004.04.008.CrossRefPubMed Petinari L, Kohn LK, Carvalho JE, Genari SC: Cytotoxicity of tamoxifen in normal and tumoral cell lines and its ability to induce cellular transformation in vitro. Cell Biol Int. 2004, 28: 531-539. 10.1016/j.cellbi.2004.04.008.CrossRefPubMed
28.
go back to reference Liang Y, Lin S-Y, Brunicardi FC, Goss J, Li K: DNA damage response pathways in tumor suppression and cancer treatment. World J Surg. 2009, 33: 661-666. 10.1007/s00268-008-9840-1.CrossRefPubMed Liang Y, Lin S-Y, Brunicardi FC, Goss J, Li K: DNA damage response pathways in tumor suppression and cancer treatment. World J Surg. 2009, 33: 661-666. 10.1007/s00268-008-9840-1.CrossRefPubMed
29.
go back to reference Thomas CG, Strom A, Lindberg K, Gustafsson JA: Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling. Breast Cancer Res Treat. 2011, 127: 417-427. 10.1007/s10549-010-1011-z.CrossRefPubMed Thomas CG, Strom A, Lindberg K, Gustafsson JA: Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling. Breast Cancer Res Treat. 2011, 127: 417-427. 10.1007/s10549-010-1011-z.CrossRefPubMed
30.
go back to reference Ellsworth DL, Ellsworth RE, Liebman MN, Hooke JA, Shriver CD: Genomic instability in histologically normal breast tissues: implications for carcinogenesis. Lancet Oncol. 2004, 5: 753-758. 10.1016/S1470-2045(04)01653-5.CrossRefPubMed Ellsworth DL, Ellsworth RE, Liebman MN, Hooke JA, Shriver CD: Genomic instability in histologically normal breast tissues: implications for carcinogenesis. Lancet Oncol. 2004, 5: 753-758. 10.1016/S1470-2045(04)01653-5.CrossRefPubMed
31.
go back to reference Khanna KK, Jackson SP: DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001, 27: 247-254. 10.1038/85798.CrossRefPubMed Khanna KK, Jackson SP: DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001, 27: 247-254. 10.1038/85798.CrossRefPubMed
32.
go back to reference Li H, Vogel H, Holcomb VB, Gu Y, Hasty P: Deletion of Ku70, Ku80, or both causes early aging without substantially increased cancer. Mol Cell Biol. 2007, 27: 8205-8214. 10.1128/MCB.00785-07.CrossRefPubMedPubMedCentral Li H, Vogel H, Holcomb VB, Gu Y, Hasty P: Deletion of Ku70, Ku80, or both causes early aging without substantially increased cancer. Mol Cell Biol. 2007, 27: 8205-8214. 10.1128/MCB.00785-07.CrossRefPubMedPubMedCentral
33.
go back to reference Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Krüger S, Feller AC, Lopens A, Diedrich K, Schwinger E, Stürzbecher HW: Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer. 2000, 88: 907-913. 10.1002/1097-0215(20001215)88:6<907::AID-IJC11>3.0.CO;2-4.CrossRefPubMed Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Krüger S, Feller AC, Lopens A, Diedrich K, Schwinger E, Stürzbecher HW: Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer. 2000, 88: 907-913. 10.1002/1097-0215(20001215)88:6<907::AID-IJC11>3.0.CO;2-4.CrossRefPubMed
34.
go back to reference Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, Alcini A, Altomare V, Fazio VM: Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene. 2001, 20: 739-747. 10.1038/sj.onc.1204148.CrossRefPubMed Pucci S, Mazzarelli P, Rabitti C, Giai M, Gallucci M, Flammia G, Alcini A, Altomare V, Fazio VM: Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies. Oncogene. 2001, 20: 739-747. 10.1038/sj.onc.1204148.CrossRefPubMed
35.
go back to reference Ahmad I, Jimenez H, Yaacob NS, Yusuf N: Tualang Honey protects keratinocytes from ultraviolet radiation-induced inflammation and DNA damage. Photochem Photobiol. 2012, 88: 1198-1204. 10.1111/j.1751-1097.2012.01100.x.CrossRefPubMedPubMedCentral Ahmad I, Jimenez H, Yaacob NS, Yusuf N: Tualang Honey protects keratinocytes from ultraviolet radiation-induced inflammation and DNA damage. Photochem Photobiol. 2012, 88: 1198-1204. 10.1111/j.1751-1097.2012.01100.x.CrossRefPubMedPubMedCentral
36.
go back to reference Lee YS, Kang YS, Lee SH, Kim JA: Role of NAD(P)H oxidase in the tamoxifen-induced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ. 2000, 7: 925-932. 10.1038/sj.cdd.4400717.CrossRefPubMed Lee YS, Kang YS, Lee SH, Kim JA: Role of NAD(P)H oxidase in the tamoxifen-induced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ. 2000, 7: 925-932. 10.1038/sj.cdd.4400717.CrossRefPubMed
37.
go back to reference Beretta G, Orioli M, Maffei Facino R: Antioxidant and radical scavenging activity of honey in endothelial cell cultures (EA.hy926). Planta Med. 2007, 73: 1182-1189. 10.1055/s-2007-981598.CrossRefPubMed Beretta G, Orioli M, Maffei Facino R: Antioxidant and radical scavenging activity of honey in endothelial cell cultures (EA.hy926). Planta Med. 2007, 73: 1182-1189. 10.1055/s-2007-981598.CrossRefPubMed
Metadata
Title
Comparison of cytotoxicity and genotoxicity of 4-hydroxytamoxifen in combination with Tualang honey in MCF-7 and MCF-10A cells
Authors
Nik Soriani Yaacob
Nur Faezah Ismail
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2014
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-14-106

Other articles of this Issue 1/2014

BMC Complementary Medicine and Therapies 1/2014 Go to the issue